AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Short Interest Up 429.9% in January

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 328,268 shares, an increase of 429.9% from the January 15th total of 61,954 shares. Based on an average trading volume of 114,674 shares, the days-to-cover ratio is currently 2.9 days. Currently, 10.0% of the shares of the stock are sold short. Currently, 10.0% of the shares of the stock are sold short. Based on an average trading volume of 114,674 shares, the days-to-cover ratio is currently 2.9 days.

Institutional Investors Weigh In On AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Sabby Management LLC acquired a new stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,855 shares of the company’s stock, valued at approximately $79,000. AIM ImmunoTech accounts for 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 22nd largest holding. Sabby Management LLC owned 1.06% of AIM ImmunoTech as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 12.02% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AIM ImmunoTech has an average rating of “Buy”.

AIM ImmunoTech Stock Performance

NYSEAMERICAN AIM opened at $0.98 on Wednesday. The stock has a 50 day moving average price of $1.27 and a 200-day moving average price of $2.01. AIM ImmunoTech has a one year low of $0.77 and a one year high of $36.00. The company has a market capitalization of $3.20 million, a P/E ratio of -0.05 and a beta of 1.26.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its quarterly earnings results on Monday, November 17th. The company reported ($1.57) earnings per share for the quarter. The company had revenue of $0.03 million for the quarter. As a group, equities analysts predict that AIM ImmunoTech will post -0.3 EPS for the current fiscal year.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.